https___antibiotic.ecdc.europa.eu_ga_bi-pairteachsocial-media-2018_cad-ata-ar-bun-ag-ecdc-lena-chinntiu-go-leanfaidh-antaibheathaigh-ar_1.xml
1.1 2.1 3.1 4.1 4.2 4.3 5.1 5.2 6.1 7.1 7.2 8.1 8.2 8.3 8.4 9.1 10.1 10.2 11.1 12.1 12.2 13.1 14.1 14.2 14.3 15.1 16.1 16.2 16.3 16.4
Use of antibiotics in animals is decreasing Use of antibiotics has decreased and is now lower in food-producing animals than in humans, says the latest report published by the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA), and the European Medicines Agency (EMA). Taking a One Health approach, the report from the three EU agencies presents data on antibiotic consumption and development of antimicrobial resistance (AMR) in Europe for 2016-2018. The significant fall in antibiotic use in food-producing animals suggests that the measures taken at country level to reduce use are proving to be effective. Use of a class of antibiotics called polymyxins, which includes colistin, nearly halved between 2016 and 2018 in food-producing animals. This is a positive development, as polymyxins are also used in hospitals to treat patients infected with multidrug-resistant bacteria. The picture in the EU is diverse – the situation varies significantly by country and by antibiotic class. For example, aminopenicillins, 3rd- and 4th-generation cephalosporins and quinolones (fluoroquinolones and other quinolones) are used more in humans than in food-producing animals, while polymyxins (colistin) and tetracyclines are used more in food-producing animals than in humans. The link between use of antibiotics and bacterial resistance The report shows that the use of carbapenems, 3rd- and 4th-generation cephalosporins and quinolones in humans is associated with resistance to these antibiotics in Escherichia coli infections in humans. Similar associations were found for food-producing animals. The report also identifies links between antimicrobial consumption in animals and AMR in bacteria from food-producing animals, which in turn is associated with AMR in bacteria from humans. An example of this is Campylobacter spp. bacteria, which are found in food producing animals and cause foodborne infections in humans. Experts found an association between resistance in these bacteria in animals and resistance in the same bacteria in humans. Fighting AMR through cooperation AMR is a significant global public health problem that represents a serious economic burden. The One Health approach implemented through the cooperation of EFSA, EMA and ECDC and the results presented in this report call for continued efforts to tackle AMR at national, EU and global level across the healthcare sectors. Antimicrobial consumption The major cause of antimicrobial resistance in microorganisms from humans remains the use of antimicrobials in human medicine, in the community and in hospitals and other healthcare settings. Read more Antimicrobial resistance Antimicrobial resistance is the ability of a microorganism (e.g., a bacterium, a virus) to resist the action of an antimicrobial agent. The major cause of antimicrobial resistance remains the use of antimicrobials in human medicine. Read more European Antibiotic Awareness Day Campaign Website European Antibiotic Awareness Day (EAAD) is a European health initiative coordinated by ECDC, which provides a platform and support for national campaigns on the prudent use of antibiotics. Each year, EAAD is marked on 18 November. Visit the campaign website of EAAD. Read more
1.1 2.1 3.1 3.2 3.3 4.1 4.2 5.1
Cad atá ar bun ag an ECDC lena chinntiú go leanfaidh antaibheathaigh ar aghaidh ag obair? Cabhraíonn an Lárionad Eorpach um Ghalair a Chosc agus a Rialú (ECDC) lena chinntiú go leanfaidh antaibheathaigh ar aghaidh ag obair trí léargas maith a thabhairt don Eoraip ar an staid chomh fada is a bhaineann le frithsheasmhacht in aghaidh antaibheathach agus tomhaltas antaibheathach, trí nuashonrú bliantúil bunaithe ar a shonraí faireachais Eorpacha a chur i dtoll a chéile, mar aon le hiarrachtaí gníomhacha úsáid stuama antaibheathach a chur chun cinn. Tá gníomhaíochtaí a bhaineann leis an ábhar seo ag an ECDC á reáchtáil faoin gclár um Frithsheasmhacht in aghaidh Ábhar Frithmhiocróbach agus Ionfhabhtuithe atá bainteach leis an gCúram Sláinte. Áirítear le príomhréimsí oibre an ECDC faireachas, faisnéis ar eipidéimí, treoir fhianaise-bhunaithe agus athbhreithnithe córasacha a fhorbairt, oiliúint, tacaíocht do Bhallstáit AE. Chomh maith leis sin, sheol an ECDC, mar aon le nuashonruithe rialta, eolaire d’acmhainní ar líne le haghaidh cosc agus rialú frithsheasmhacht in aghaidh ábhar frithmhiocróbach agus ionfhabhtuithe bainteach leis an gcúram sláinte chun tacú le Ballstáit an AE a bhfuil treoirlínte náisiúnta le forbairt acu. Ó 2008 i leith, tá an Lá Feasachta Eorpach maidir le hÚsáid Antaibheathach á chomhordú ag an ECDC, tionscnamh sláinte poiblí a bhfuil sé mar aidhm leis ardán agus tacaíocht a sholáthar d’fheachtais náisiúnta maidir le húsáid stuama antaibheathach. Gach bliain ar fud na hEorpa, reáchtáiltear EAAD ar an 18 Samhain. Chomh maith leis sin, oibríonn an ECDC i gcomhpháirt le heagraíochtaí éagsúla gairmiúla agus othar, an Coimisiún Eorpach, an tÚdarás Eorpach um Shábháilteacht Bia, an Ghníomhaireacht Leigheasra Eorpach agus Oifig Réigiúnach na hEagraíochta Domhanda Sláinte don Eoraip, mar aon le feachtais idirnáisiúnta sna Stáit Aontaithe, san Astráil, sa Nua-Shéalainn, i gCeanada agus sa tSeapáin, chun tabhairt faoi roinnt gníomhaíochtaí chun dul i ngleic le frithsheasmhacht in aghaidh ábhar frithmhiocróbach